Core Insights - Vivoryon Therapeutics N.V. will report its H1 2025 financial results and operational progress on September 4, 2025 [1] - The company focuses on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [3] Financial Reporting - The financial results will cover the period ended June 30, 2025, and will be available for download on the company's website [1] - A conference call and webcast will be held on the same day to discuss the results [2] Company Overview - Vivoryon is a clinical stage biotechnology company dedicated to innovative treatments for kidney-related inflammatory and fibrotic disorders [3] - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 作为共生微生物组的一部分，肿瘤内微生物组在肿瘤免疫中的调控作用正逐渐被揭示。然而，肿瘤内微生物组与免疫检查点抑制剂 （ICI） 临床治疗效果之间的关 系，目前仍不清楚。 免疫检查点抑制剂 （ICI） 如今在多种恶性肿瘤 （例如黑色素瘤、非小细胞肺癌、肾细胞癌等） 的治疗中得到广泛应用，并被视为癌症治疗领域的一项重大突 破。然而，只有一部分患者 （约 20%） 能从 ICI 治疗中持久获益，由于原发性和获得性耐药，治疗失败的情况非常普遍。因此，我们迫切需要探索其耐药机 制，并寻找提高 ICI 临床获益的方法。 随着测序技术和生物信息学的发展，越来越多的证据表明， 肠道微生物组 在免疫检查点抑制剂 （ICI） 治疗效果中发挥着至关重要的作用。一些正在进行中的将 粪菌移植与免疫检查点抑制剂联合使用的临床试验已显示出令人振奋的结果，这凸显了靶向共生微生物组在增强免疫治疗效果方面的潜在应用。 近期的一些研究发现表明，肿瘤微环境 （TME） 内的 肿瘤内微生物组 与癌症的发展、预后以及治疗反应存在关联。结合临床样本和临床前模型的研究表明，某 些肿瘤内微生物能够促进癌症的发展、转移以 ...

当戴尔电脑在20世纪90年代实现股价269倍增长时，英特尔和微软正垄断着计算机行业的核心技术；当硅图公司（Silicon Graphics）因供应链失控从45美元 股价崩盘至13美元时，它仍是三维图形技术的全球霸主；当默克制药在生物技术革命中坚持垂直整合时，华尔街正疯狂押注新兴生物科技公司——这些看似 矛盾的商业现象背后，隐藏着当今投资世界最残酷的真相： 技术护城河正在失效，供应链已成为企业生死存亡的DNA，而决定其价值的核心指标，叫做"脉动速度"。 1.戴尔谜题：零专利企业的269倍增长奇迹 1998年，戴尔电脑的股价比90年代初暴涨了269倍，把英特尔、微软这些"技术大佬"都甩在身后。这简直是个商业奇迹——戴尔自己既不造芯片（依赖英特 尔），也不做操作系统（靠微软），还天天被懂行的消费者比价，周围全是IBM、惠普这样的巨头对手。它靠什么赢？其制胜法宝正是"供应链设计"： ·零成品库存：订单直达工厂，24小时组装发货 ·零分销层级：砍掉经销商，直连终端客户 2. 硅图惨案：技术巨头的链式崩溃 1995年的硅图公司如日中天：年赚20亿美金，股价冲上45美元，连《侏罗纪公园》的恐龙都是它"画"出来的。这家拥有顶 ...

Akeso says its closely-watched lung cancer drug has definitively demonstrated for the first time that it could help some patients live longer, potentially boosting its prospects for approval in the US https://t.co/qtXfv9b5bp ...

A biotechnology industry exchange-traded fund (ETF) invests in companies that combine biology and technology to develop innovative products and services. https://t.co/aIu5fjfFln ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Soleno and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential cla ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claim ...

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 9th at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time. A live webcast of the session will be available on the Investor sectio ...

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update. Sana will present at Citi’s 2025 Biopharma Back-to-School Conference at 3:15 p.m. ET on Tuesday, September 2, 2025.Sana will present at the 2025 Wells Fargo Healthcare Conference at 8:0 ...

MENLO PARK, Calif., Aug. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, Sep. 9 at 1:50 p.m. ET. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after t ...